The Impact of Hormone Receptor Status on the Clinical Efficacy of the New-Generation Aromatase Inhibitors: A Review of Data from First-Line Metastatic Disease Trials in Postmenopausal Women-Reference-Cited by-同舟云学术

The Impact of Hormone Receptor Status on the Clinical Efficacy of the New-Generation Aromatase Inhibitors: A Review of Data from First-Line Metastatic Disease Trials in Postmenopausal Women

Published:2004-05 Issue:3 Volume:10 Page:211-217
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast Journal

Author:

Buzdar Aman U.,Vergote Ignace,Sainsbury Richard

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1075-122X.2004.21320.x/fullpdf

Reference15 articles.

1. Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications

2. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

3. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

4. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.

5. Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Novel Cancer Biomarkers for Diagnosis and Prognosis;Cancer Biomarkers in Diagnosis and Therapeutics;2022

2. Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing;Breast Disease;2019

3. Biomarkers in Breast Cancer;Biomarker - Indicator of Abnormal Physiological Process;2018-09-05

4. Predictive and Prognostic Marker Testing in Breast Pathology;Breast Pathology;2017

5. Clinical Aspects of Estrogen and Progesterone Receptors and ERBB2 Testing;Breast Disease;2016